Joaquín Gavilá

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini, Núria Chic, Fara Brasó‐Maristany et al. · npj Breast Cancer · 2021 · 691 citations · Full text

Medicine, Cancer Biology, Oncology +10

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat, Cristina Saura, Tomás Pascual et al. · The Lancet Oncology · 2019 · 201 citations

Medicine, Oncology, Pharmacology +16

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso‐Sousa et al. · Breast Cancer Research · 2020 · 146 citations · Full text

Medicine, Oncology, Pharmacology +17

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, <i>ERBB2</i>-Negative Advanced Breast Cancer

Antonio Llombart‐Cussac, José Manuel Pérez-García, Meritxell Bellet et al. · JAMA Oncology · 2021 · 106 citations · Full text

Medicine, Oncology, Pharmacology +16